Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP2151 in Herpes Simplex
NCT01959295Phase 3
Key facts
- Status
- Completed
- Start
- Aug 2013
- Primary completion
- Apr 2015
- Countries
- 1
- Sponsor
- Maruho Co., Ltd.
- Modality
- Small Molecules
- Drugs
- Amenamevir
- Conditions
- herpes simplex (HSV)
01
Overview
Phase 3, randomised, double-blind trial in herpes simplex (HSV) comparing ASP2151 with Placebo (2 arms). Primary endpoint: Percentage of Participants With Healing by Day 8. Started Aug 2013; status: completed.
02
Design
2 arms- Study design
- RandomizedDouble-blind
ASP2151
Amenamevir 200 mg once daily
Placebo
Placebo once daily
03
Who it enrols
Adult patients (20-79 years) with moderate to severe recurrent herpes simplex (labial/facial or genital) who can start treatment within 48 hours of rash onset. Patients with significant renal, hepatic, or immune impairment are excluded.
04
Endpoints
Primary
Percentage of Participants With Healing by Day 8
Secondary
Time to Healing
Time to Complete Crusting
Time to Virus Disappearance
05
Results
Not all primary endpoints met
Beyond the preview
Go deeper on NCT01959295.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01959295.